AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Cullinan Oncology LLC (NASDAQ:CGEM)
15.03 USD
+0.590 4.086%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.44 |
|---|---|
| Change | +0.590 4.086% |
| 52 W H/L (in USD) | 16.740/5.680 |
| EBITDA (in USD) | -241.337M |
| PE Ratio | -- |
| Volume | 3117265 |
| Diluted Eps TTM | -3.36 |
| Total Assets (in USD) | 448.374M |
|---|---|
| Total Liabilities (in USD) | 39.644M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 88.332M |
| Market Cap (in USD) | 860.682 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 18.943M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Employees: 109
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Nadim Ahmed | Pres, CEO & Director | 1968 |
| 2. | Mr. Jeffrey Trigilio | CFO & Treasurer | 1985 |
| 3. | Dr. Patrick A. Baeuerle Ph.D. | Chief Scientific Officer | 1958 |
| 4. | Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corp. Sec. | 1978 |
| 5. | Ms. Rose Weldon | VP of Communications | NA |
| 6. | Mr. Steve Andre | Chief HR Officer | NA |
| 7. | Dr. Corinne Savill Ph.D. | Chief Bus. Officer | 1959 |
| 8. | Dr. Jennifer Michaelson Ph.D. | Chief Devel. Officer | 1968 |
| 9. | Ms. Kerry Whalen | Sr. Director of Preclinical & Early Devel. | NA |
| 10. | Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer | 1971 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -219.879M | -167.458M | -169.223M | 151.316M | -67.485M |
| Minority Interest | 0M | 0.192M | 1.939M | -2.019M | -1.915M |
| Net Income | -219.879M | -167.383M | -153.162M | 111.214M | -65.04M |
| Selling General Administrative | 54.246M | 52.816M | 42.493M | 40.189M | 29.146M |
| Gross Profit | -0.311M | -0.306M | -0.31M | - | 18.943M |
| Reconciled Depreciation | 0.311M | 0.306M | 0.31M | 0.093M | 0.053M |
| Ebit | -241.959M | -167.458M | -190.649M | 144.648M | -68.007M |
| Ebitda | -241.648M | -167.152M | -190.339M | -408.922M | -67.954M |
| Depreciation And Amortization | 0.311M | 0.306M | 0.31M | -553.57M | 0.053M |
| Operating Income | -241.648M | -196.919M | -191.089M | 144.648M | -67.954M |
| Other Operating Expenses | 241.648M | 196.919M | 191.089M | 132.137M | 86.897M |
| Interest Expense | - | - | - | -562.35M | 65.45M |
| Tax Provision | 0M | 0.117M | -14.122M | 42.121M | - |
| Interest Income | 22.212M | 29.66M | 21.627M | 6.611M | 0.477M |
| Net Interest Income | 22.212M | 29.66M | 21.627M | 6.611M | 0.477M |
| Income Tax Expense | - | 0.117M | -14.122M | 42.121M | -2.445M |
| Total Revenue | 0M | 0M | 0M | 0M | 18.943M |
| Total Operating Expenses | 241.648M | 196.613M | 191.089M | 132.137M | 86.897M |
| Cost Of Revenue | 0.311M | 0.306M | 0.31M | - | - |
| Total Other Income Expense Net | 21.769M | 29.461M | 21.866M | 6.668M | 0.469M |
| Net Income From Continuing Ops | -219.879M | -167.575M | -155.101M | 109.195M | -65.57M |
| Net Income Applicable To Common Shares | - | - | - | 111.214M | -65.57M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 448.374M | 621.824M | 485.096M | 561.117M | 437.185M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 8.86M | 12.691M | 13.124M | 7.18M | 6.098M |
| Total Liab | 39.644M | 31.496M | 31.201M | 26.088M | 11.811M |
| Total Stockholder Equity | 408.73M | 590.328M | 453.703M | 535.029M | 422.576M |
| Other Current Liab | 36.12M | 27.663M | 24.204M | 18.239M | 8.577M |
| Common Stock | 0.006M | 0.006M | 0.004M | 0.005M | 0.004M |
| Capital Stock | 0.006M | 0.006M | 0.004M | 0.005M | 0.004M |
| Retained Earnings | -588.119M | -368.24M | -200.857M | -47.695M | -158.909M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | 0.459M | 6.322M |
| Cash | 88.332M | 83.005M | 98.434M | 550.118M | 430.863M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 37.741M | 30.647M | 28.137M | 22.498M | 11.746M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -85.649M | -80.854M | -94.844M | -544.929M | -430.863M |
| Short Term Debt | 0.78M | 1.302M | 1.44M | 1.599M | - |
| Short Long Term Debt | - | - | - | 0.178M | - |
| Short Long Term Debt Total | 2.683M | 2.151M | 3.59M | 5.189M | - |
| Other Stockholder Equity | 995.823M | 958.695M | 654.685M | 585.32M | 582.319M |
| Property Plant Equipment | - | - | - | 1.174M | 0.077M |
| Total Current Assets | 386.756M | 414.668M | 480.191M | 474.472M | 296.564M |
| Long Term Investments | 58.27M | 204.44M | 0M | 80.882M | 140.397M |
| Short Term Investments | 289.564M | 315.972M | 368.633M | 311.14M | 230.692M |
| Net Receivables | - | 3M | 5.4M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | -5.4M | - | - |
| Accounts Payable | 0.841M | 1.682M | 2.493M | 2.66M | 3.169M |
| Accumulated Other Comprehensive Income | 1.02M | -0.133M | -0.129M | -2.601M | -0.838M |
| Non Currrent Assets Other | 0.297M | 0.366M | 0.459M | 0.459M | 0.147M |
| Non Current Assets Total | 61.618M | 207.156M | 4.905M | 86.645M | 140.621M |
| Capital Lease Obligations | 2.683M | 2.151M | 3.59M | 5.011M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 180.038M | -136.314M | 35.806M | -24.983M | -333.775M |
| Total Cashflows From Investing Activities | 179.989M | -136.314M | 35.806M | 248.975M | -333.775M |
| Total Cash From Financing Activities | 1.088M | 266.188M | 40.751M | -25.933M | 268.784M |
| Net Income | -219.879M | -167.575M | -153.162M | 109.195M | -67.485M |
| Change In Cash | 5.327M | -15.429M | -57.718M | 96.378M | -108.424M |
| Begin Period Cash Flow | 83.005M | 98.434M | 156.152M | 59.774M | 168.198M |
| End Period Cash Flow | 88.332M | 83.005M | 98.434M | 156.152M | 59.774M |
| Total Cash From Operating Activities | -175.75M | -145.303M | -134.275M | -126.664M | -43.433M |
| Depreciation | 0.311M | 0.306M | 0.31M | 0.093M | 0.053M |
| Other Cashflows From Investing Activities | - | - | 0.036M | 275.091M | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | -23.733M | 271.472M |
| Other Cashflows From Financing Activities | 1.088M | 3.536M | 0.538M | -23.739M | 1.516M |
| Capital Expenditures | 0.049M | 0M | 0.208M | 1.133M | 1.133M |
| Change In Working Capital | 14.084M | -0.389M | -0.339M | 11.176M | -3.541M |
| Other Non Cash Items | -6.306M | -15.469M | -11.522M | -275.085M | 0.067M |
| Free Cash Flow | -175.799M | -145.303M | -134.483M | -127.797M | -43.433M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 1855966 |
| 2. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 1368049 |
| 3. | iShares Russell 2000 ETF | 2 months ago | 1304914 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 570181 |
| 5. | Fidelity Small Cap Index | 4 months ago | 523603 |
| 6. | Nuveen Quant Small Cap Equity R6 | 3 months ago | 463244 |
| 7. | iShares Russell 2000 Value ETF | 2 months ago | 460225 |
| 8. | T. Rowe Price New Horizons | 2 months ago | 424028 |
| 9. | International Biotechnology Ord | 5 months ago | 343667 |
| 10. | Russell 2000 Equity Index Fund B | 5 months ago | 336161 |
| 11. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 334276 |
| 12. | iShares Biotechnology ETF | 2 months ago | 324101 |
| 13. | Xtrackers S&P 500 Swap ETF 1C | 5 months ago | 307851 |
| 14. | T. Rowe Price Integrated US Sm Gr Eq | 2 months ago | 297800 |
| 15. | CREF Total Global Stock Account R3 | 3 months ago | 295440 |
| 16. | Fidelity Extended Market Index | 3 months ago | 271481 |
| 17. | Vanguard Russell 2000 ETF | 2 months ago | 265627 |
| 18. | Schwab US Small-Cap ETF™ | 2 months ago | 250504 |
| 19. | T. Rowe Price New Horizons Tr-A | 2 months ago | 197314 |
| 20. | Dimensional US Small Cap ETF | 2 months ago | 192755 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Lynx1 Capital Management, LP | 5 months ago | 8963500 |
| 2. | MPM Oncology Impact Management LP | 5 months ago | 7648268 |
| 3. | Bvf Inc | 5 months ago | 5750683 |
| 4. | BlackRock Inc | 8 months ago | 4169962 |
| 5. | The Goldman Sachs Group Inc | 5 months ago | 721864 |
| 6. | Great Point Partners LLC | 5 months ago | 634032 |
| 7. | Renaissance Technologies Corp | 5 months ago | 631706 |
| 8. | Vanguard Group Inc | 5 months ago | 3298504 |
| 9. | Kynam Capital Management, LP | 5 months ago | 3114132 |
| 10. | Blue Owl Capital Holdings LP | 5 months ago | 2350972 |
| 11. | Affinity Asset Advisors, LLC | 5 months ago | 1932106 |
| 12. | RTW INVESTMENTS, LLC | 5 months ago | 1705960 |
| 13. | State Street Corp | 8 months ago | 1677314 |
| 14. | Franklin Resources Inc | 8 months ago | 1416036 |
| 15. | VR Adviser, LLC | 5 months ago | 1379965 |
| 16. | Geode Capital Management, LLC | 5 months ago | 1302262 |
| 17. | BOOTHBAY FUND MANAGEMENT, LLC | 5 months ago | 1237043 |
| 18. | Siren, L.L.C. | 5 months ago | 1193410 |
| 19. | Nextech Invest, Ltd. | 5 months ago | 1141145 |
| 20. | Dimensional Fund Advisors, Inc. | 5 months ago | 848769 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...